BCRX250516P2000
- 0.00
- 0.000.00%
BioCryst Pharmaceuticals Newsroom
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18
BioCryst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 5, 2025
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11
Executive Reshuffles: CVS, NNDM, and DBX
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11
Express News | RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $11 Price Target
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry
BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis
Express News | BioCryst Pharmaceuticals - on April 7, Jon P. Stonehouse Appointed Interim CFO & Interim Principal Accounting Officer - SEC Filing
Express News | Needham Reiterates Buy on BioCryst Pharma, Maintains $15 Price Target
Express News | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BioCryst to Present at Upcoming Investor Conference
Institutional Investors Control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Were Rewarded Last Week After Stock Increased 4.9%
BioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Express News | BioCryst Pharmaceuticals Inc - Seeks to Block FDA Approval of Generic Orladeyo Until Patent Expiration
Executive Reshuffles: SBUX, KR, and LVS